Evaluation of gene expression in human lymphocytes activated in the presence of melatonin

International Immunopharmacology

Volumn 2, Issue 7, 2002, Pages 885-892

  Capelli, Enrica ^a   Campo, Ilaria ^a   Panelli, Simona ^b   Damiani, Giuseppe ^c   Barbone, Maria Grazia Santagostino ^a   Lucchelli, Adele ^a   Cuccia, Mariaclara ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CNR   (Italy)

Author keywords

LAK cells; Melatonin; T lymphocytes

Indexed keywords

HLA DR ANTIGEN; MELATONIN; MESSENGER RNA; PHYTOHEMAGGLUTININ; THYMOSIN BETA10; TUMOR REJECTION ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; LYMPHOKINE ACTIVATED KILLER CELL; NORMAL HUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY;

CELL DIVISION; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; LYMPHOCYTE ACTIVATION; MELATONIN; PHYTOHEMAGGLUTININS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 0036310205     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00021-8     Document Type: Article

References (22)

1. The immunoendocrine role of melatonin
2. High affinity binding of melatonin by human circulating T lymphocytes (CD 4+)
3. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events
4. Melatonin in cancer patients and in tumour-bearing animals
5. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status
6. Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen alone
7. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation
8. Adoptive T-cell immunotherapy of cancer
9. Allogeneic cell therapy in murine B-cell leukemia (BCL1). The role of non-activated and rIL-2 activated CD4+ and CD8+ T cells in immunotherapy for leukemia
10. Identification of mRNA differentially expressed in lymphocytes following Interleukin-2 activation
11. A novel member of the Ras proto-oncogene family: Domain architecture, tissue-specific expression and evolutionary conservation
12. S phase specific formation of the human Rad51 protein nuclear foci in lymphocytes
13. Cell cycle regulation of the glyceraldehyde-3-phosphate deidrogenase/uracil DNA glycosylase gene in normal human cells
14. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-β, rTNF-α, rIFN-γ, rIL4 and their combinations
15. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
16. Heat shock protein-peptide complexes for use in vaccines
17. Tumor-specific cell surface expression of the KDEL containing endoplasmic reticular heat shock protein gp96
18. Tumor rejection antigen gp96/grp94 is an ATPase: Implication for protein folding and antigen presentation
19. Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner
20. Hematopioietic effect of melatonin involvement of type 1 kappa-opioid receptor on bone marrow macrophages and interleukin-1
21. Bcl-2 and the regulation of programmed cell death